COMPUGEN LTD

CGEN · Nasdaq · Israel

Share price · CGEN

$1.96-0.42 (-17.65%) 3M

close as of 2026-11-18 · 24h delayed · vol 146K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CGEN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+9.2%
  2. 22 Oct 2026-7.5%
  3. 25 Aug 2026+10.8%
  4. 20 Aug 2026+8.6%
  5. 2 Mar 2026+24.3%
  6. 20 Jan 2026-7.6%
  7. 16 Jan 2026+11.8%

    Nothing announced by CGEN that day or the session before.

  8. 15 Jan 2026+6.6%
  9. 9 Jan 2026+14.6%

Share of unusual movement by asset

For each asset, the share of CGEN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—86%

No dated announcements about its assets since 2 Jul 2024.

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
8Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
PD-1 and TIGITMultispecific antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaBiliary Tract CancerGastric CancerBladder / Urothelial CancerEndometrial Cancer
Urothelial Carcinoma
Phase 1/2
PVRIG (CD112R)Monoclonal antibody
Ovarian Cancer
Phase 1
TIGITMonoclonal antibody
Multiple Myeloma

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
March 2027 (1)
COM701Phase 1/2Ovarian Cancer, Ovarian Cancer Recurrent
Est. primary completion 2027-03 · NCT06888921 · CT.gov ↗
What to watch
May 2027 (1)
RilvegostomigPhase 2Gastric Cancer
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
September 2027 (1)
RilvegostomigPhase 1/2Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
Est. primary completion 2027-09-29 · NCT05123482 · CT.gov ↗
What to watch
October 2027 (1)
RilvegostomigPhase 2Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer …
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
November 2027 (2)
RilvegostomigPhase 2Gastroesophageal Adenocarcinoma
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
RilvegostomigPhase 2Gastric Cancer
Est. primary completion 2027-11-30 · NCT05702229 · CT.gov ↗
What to watch
2028 (2)
June 2028 (2)
RilvegostomigPhase 1/2Non-Small-Cell Lung Carcinoma
Est. primary completion 2028-06-01 · NCT04995523 · CT.gov ↗
What to watch
RilvegostomigPhase 3Biliary Tract Cancer
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
2029 (10)
January 2029 (2)
RilvegostomigPhase 3Biliary Tract Cancer
Est. primary completion 2029-01-02 · NCT06109779 · CT.gov ↗
What to watch
RilvegostomigPhase 3Endometrial Cancer
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
February 2029 (1)
RilvegostomigPhase 1/2Advanced or Metastatic Non-small Cell Lung Cancer
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
March 2029 (1)
RilvegostomigPhase 1/2Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Est. primary completion 2029-03-16 · NCT06005493 · CT.gov ↗
What to watch
April 2029 (2)
RilvegostomigPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
RilvegostomigPhase 3HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
July 2029 (1)
RilvegostomigPhase 3Biliary Tract Cancer
Est. primary completion 2029-07-31 · NCT07221253 · CT.gov ↗
What to watch
August 2029 (1)
RilvegostomigPhase 3Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Est. primary completion 2029-08-16 · NCT07431281 · CT.gov ↗
What to watch
October 2029 (1)
RilvegostomigPhase 1/2Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma …
Est. primary completion 2029-10-02 · NCT07115043 · CT.gov ↗
What to watch
December 2029 (1)
RilvegostomigPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-12-28 · NCT06357533 · CT.gov ↗
What to watch
2030 (6)
January 2030 (1)
RilvegostomigPhase 3Carcinoma, Non-Small Cell Lung
Est. primary completion 2030-01-17 · NCT06868277 · CT.gov ↗
What to watch
March 2030 (1)
RilvegostomigPhase 3Hepatocellular Carcinoma
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
May 2030 (1)
RilvegostomigPhase 2Non-small Cell Lung Cancer
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
July 2030 (1)
RilvegostomigPhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-07-01 · NCT06692738 · CT.gov ↗
What to watch
September 2030 (1)
RilvegostomigPhase 3High-risk Muscle Invasive Urothelial Carcinoma
Est. primary completion 2030-09-11 · NCT07720284 · CT.gov ↗
What to watch
November 2030 (1)
RilvegostomigPhase 3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2030-11-18 · NCT06627647 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$73M$23M$91M+ $9.3M short-term inv.—$32M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$28M$25M$18M+ $24M short-term inv.$3.6M$50M operating cash flowreport ↗
2023-FY$33M$34M$14M+ $12M short-term inv.$4.7M-$36M operating cash flowreport ↗
2022-FY$7.5M$31M$11M+ $0 short-term inv.$8.4M-$35M operating cash flowreport ↗
2021-FY$6.0M$29M$8.5M+ $109M short-term inv.$8.6M-$23M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 12 sales ($126K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-29Mahler Michelle · Chief Medical OfficerAward / grant13,500——Form 4
2026-07-29ZWEIFACH SANFORD S · directorAward / grant7,500——Form 4
2026-07-29Halevy Gilead · directorAward / grant7,500——Form 4
2026-07-29Hukkelhoven Mathias · directorAward / grant7,500——Form 4
2026-07-29Livnat Savitzky Kinneret · directorAward / grant7,500——Form 4
2026-07-29Kredo Russo Sharon · SVP, Research & DiscoveryAward / grant18,000——Form 4
2026-07-29Ferre Pierre · Chief Operating OfficerAward / grant (derivative)70,000——Form 4
2026-07-29Perry Eran · directorAward / grant7,500——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 77 reporting institutions held 14.2M shares ($30.7M, 15.0% of shares outstanding).

#InstitutionSharesValue
1SILVERARC CAPITAL MANAGEMENT, LLC3,315,845$7.1M
2RENAISSANCE TECHNOLOGIES LLC1,632,988$3.5M
3MORGAN STANLEY1,053,229$2.2M
4ARK Investment Management LLC1,049,873$2.2M
5NOMURA ASSET MANAGEMENT INTERNATIONAL INC.1,020,000$2.2M
6Taylor Frigon Capital Management LLC848,043$1.8M
7NORTHERN TRUST CORP650,868$1.4M
8TWO SIGMA INVESTMENTS, LP521,587$1.1M
9STATE STREET CORP415,366$885K
10Yelin Lapidot Holdings Management Ltd.318,852$679K
11UBS Group AG306,708$653K
12WELLS FARGO & COMPANY/MN3,100$646K
13DAFNA Capital Management LLC257,783$549K
14MARSHALL WACE, LLP244,480$521K
15MILLENNIUM MANAGEMENT LLC168,927$360K